Why the study?
Temporal trends and the benefits of long-term oral cardiovascular medications on acute heart failure outcomes remained uncertain.
Have mortality and readmission rates after acute heart failure improved over the past four decades, and are these trends associated with the use of oral cardiovascular therapies?
Population
15 million AHFs across 285 studies
Comparison
Temporal trends and proportions of oral cardiovascular therapies
Design
Systematic review and meta-regression
Follow-up
30-day and 1-year
Authors
Loading...
May support wider RAASi plus beta-blocker use after AHF; extends observational survival associations but leaves readmission impact and causality open.
Have mortality and readmission rates after acute heart failure improved over the past four decades, and are these trends associated with the use of oral cardiovascular therapies?
Survival after acute heart failure has improved globally over the past four decades, likely associated with increased use of oral neurohormonal antagonists, though readmission rates remain unchanged.
Kimmoun et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: